Pfizer Highlights Oncology Pipeline With 60+ Abstracts At ASCO 2025

Pfizer Inc. is a clinical-stage pharmaceutical company that develops innovative targeted therapeutics with advanced technologies. The firm has announced that it will present data from over 60 studies at the 2025 ASCO Annual Meeting, which includes key breast, genitourinary, thoracic, hematologic, and colorectal cancers. Two late-breaking oral presentations will be featured in ASCO’s pre-meeting press briefing on May 27th. Final OS and PFS results from the Phase 3 BREAKWATER trial studied the combination of BRAFTOVI® + cetuximab + mFOLFOX6 in BRAF-mutant mCRC, along with the PFS data from the VERITAC-2 study of vepdegestrant in ER+/HER2- a/mBC, in partnership with Arvinas.

“This has already been a significant year for Pfizer’s Oncology pipeline, with multiple Phase 3 data readouts and regulatory approvals, and the initiation of pivotal registrational programs across our major tumor areas of focus,” said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research & Development, Pfizer. “The depth and diversity of our data presentations at ASCO are building on that momentum to bring us closer to our goal of delivering eight breakthrough cancer medicines by 2030.”

Pfizer will share new insights from late-stage programs, including 5-year survival results from the ARCHES study of XTANDI® in metastatic hormone-sensitive prostate cancer and early combination data from the MagnetisMM-6 study that evaluated ELREXFIO® + daratumumab + lenalidomide in newly diagnosed multiple myeloma patients not eligible for transplant.

“Our data at ASCO this year reflect how we are strategically progressing our deep pipeline of next-generation cancer medicines while simultaneously extending the impact of our foundational therapies to reach more people living with cancer,” said Megan O’Meara, Head of Early-Stage Development and Interim Head of Late-Stage Development, Pfizer Oncology. “Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal Phase 3 trials this year.”

The company will debut Phase 1 data on two investigational vedotin ADCs combined with pembrolizumab in thoracic cancers, and explore novel epigenetic regulators, including mevrometostat (EZH2 inhibitor) and PF-07248144 (KAT6 inhibitor) in metastatic prostate and breast cancer. Pfizer’s presentations reinforce its strategy of combining targeted therapies, ADCs, and immuno-oncology agents to expand treatment options across solid tumours and hematologic malignancies.